TABLE 5

Prognostic performance of different parameters for the identification of patients with severe disease (primary outcome) and optimal therapy response (secondary outcome)

Cut-off valueAUC (95% CI)Sensitivity (%, 95% CI)Specificity (%, 95% CI)NPV (%, 95% CI)PPV (%, 95% CI)OR (95% CI)
Identification of patients at a severe disease state (primary outcome); n=17
 MR-proANP pmol·L−12270.91 (0.86–0.97)93 (68–100)80 (70–88)99 (92–100)43 (33–54)56 (6.9–454.3)
 Copeptin pmol·L−110.90.70 (0.57–0.83)67 (38–88)71 (61–80)93 (86–96)27 (19–38)1.5 (1.2–1.9)
 NT-proBNP ng·L−110500.89 (0.82–0.96)100 (79–100)65 (54–75)100 (100)31 (26–38)4.9 (1.5–15.8)
 eGFR mL·min−1·m−2660.68 (0.52–0.83)53 (28–77)82 (73–90)91 (87–95)33 (21–48)5.3 (1.8–15.8)
 6-min walk distance m3550.72 (0.52–0.92)67 (30–93)78 (66–88)94 (85–97)33 (20–49)7.2 (1.5–32.9)
 WHO functional classIII0.67 (0.53–0.81)100 (80–100)11 (5–19)100 (100)15 (5–19)1.2 (1.1–1.3)
 TAPSE mm180.70 (0.54–0.85)67 (86–96)69 (57–79)93 (86–96)26 (18–36)4.4 (1.4–14.3)
Identification of optimal therapy responders (secondary outcome); n=53
 MR-proANP pmol·L−11230.70 (0.60–0.79)87 (74–94)45 (31–59)82 (68–91)53 (47–59)5.2 (2.0–13.5)
 Copeptin pmol·L−110.10.58 (0.47–0.69)81 (68–91)39 (27–53)74 (60–85)49 (43–55)2.8 (1.2–6.7)
 NT-proBNP ng·L−13690.64 (0.53–0.75)96 (85–100)28 (16–43)90 (68–97)49 (44–54)8.4 (1.8–39.2)
 eGFR mL·min−1·m−2890.66 (0.56–0.77)68 (54–80)66 (52–78)74 (65–81)59 (49–69)4.1 (1.9–9.2)
 6-min walk distance m4940.72 (0.61–0.84)63 (45–79)77 (61–88)74 (64–82)66 (52–78)5.6 (2.1–15.0)
 WHO functional classIII0.65 (0.55–0.76)96 (87–100)14 (6–26)84 (54–96)45 (42–48)4.3 (0.86–21.0)
 TAPSE mm180.58 (0.45–0.70)60 (43–75)24 (12–45)45 (30–61)36 (30–44)0.47 (0.18–1.2)

AUC: area under the curve; CI: confidence interval; NPV: negative predictive values; PPV: positive predictive values; OR: odds ratio; MR-proANP: mid-regional pro-atrial natriuretic peptide; NT-proBNP: N-terminal pro-B-type natriuretic peptide; eGFR: estimated glomerular filtration rate; WHO: World Health Organization; TAPSE: tricuspid annular plan systolic excursion.